Abstract 349P
Background
Euphorbia hirta has many health benefits for enhancing human health. It exhibits various antioxidant properties. Our aim was to investigate the effects of several polyphenols from Euphorbia hirta ethanolic extract on the growth and metastatic potential of B16F10 melanoma cells in vitro and to measure the observable changes of cell morphology upon exposure to the extract.
Methods
The cytotoxic activity of the Euphorbia hirta extract on B16F10 melanoma cell line was investigated in vitro using 3‐ (4, 5‐dimethyl thiazol‐2yl) ‐2, 5‐diphenyl tetrazolium bromide (MTT). B16F10 (human Melanoma) cell lines were cultured in DMEM supplemented with 10% inactivated Fetal Bovine Serum (FBS), penicillin (100 IU/ml), streptomycin (100 μg/ml) and amphotericin B (5 μg/ml) in an humidified atmosphere of 5% CO2 at 37 °C until confluent. The cells were dissociated with Trypsin solution (0.2% trypsin, 0.02% EDTA in PBS). The stock cultures were grown in 25 cm2 culture flasks and all experiments were carried out in 96 micro-titer plates. After culturing and proliferation of B16F10 cells, these cells were exposed to various ethanolic extract of E hirta. The potency of plant extract concentration was calculated in terms of a percent decrease in viable B16F10 cells as compared to the control value.
Results
The in vitro growth of B16F10 melanoma cells in the presence of a series of polyphenolic compounds (10–9 to 10–5 M) was evaluated. Quercetin, apigenin, EGCG, resveratrol, curcumin, and tamoxifen inhibited the growth of B16F10 cells in a concentration‐dependent manner. The concentrations needed to inhibit cell growth by 50% (IC50) are reported. The results of MTT assay test showed that the ethanol extract of Euphorbia hirta was tested for the anticancer activity and it showed the most effective inhibition of B16F10 cells proliferation.
Conclusions
We assessed the cytotoxic effect of Euphorbia hirta extract in cell culture. In defiance of astonishing advances in modern medicine, such as surgery, radiotherapy, chemotherapy, and immunotherapy, melanoma cancer disease remains a worldwide health problem, thus endeavoring the search for a new alternate approach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract